Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck released positive Phase III data on its follow-on biologic, insulin glargine, for diabetes at the American Diabetes Association Scientific Sessions, positioning the insulin category for fierce pricing competition.

You may also be interested in...



Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets

Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.

Agios CEO Fouse On Building A Sustainable Business Model

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel